Annual report pursuant to Section 13 and 15(d)

Revenue from Contracts with Customers

v3.19.3.a.u2
Revenue from Contracts with Customers
12 Months Ended
Sep. 30, 2019
Revenue from Contracts with Customers [Abstract]  
Revenue from Contracts with Customers

Note 4 – Revenue from Contracts with Customers



The Company generates nearly all its revenue from direct product sales. Revenue from direct product sales is generally recognized when the customer obtains control of the product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Sales taxes and other similar taxes that the Company collects concurrent with revenue-producing activities are excluded from revenue.



The amount of consideration the Company ultimately receives varies depending upon sales discounts, and other incentives that the Company may offer, which are accounted for as variable consideration when estimating the amount of revenue to recognize. The estimate of variable consideration requires significant judgment. The Company includes estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely upon an assessment of current contract sales terms and historical payment experience.



Product returns are typically not significant because returns are generally not allowed unless the product is damaged at time of receipt.



The Company’s revenue is from direct product sales of FC2 in the global public sector, sales of FC2 in the U.S. prescription channel, and sales of PREBOOST® medicated wipes for the treatment of premature ejaculation. The following table presents net revenues from these three categories for the years ended September 30, 2019 and 2018:





 

 

 

 

 



2019

 

2018

FC2

 

 

 

 

 

Global public sector

$

16,835,998 

 

$

13,458,365 

U.S. prescription channel

 

14,083,368 

 

 

2,394,219 

Total FC2

 

30,919,366 

 

 

15,852,584 

PREBOOST®

 

884,021 

 

 

11,899 

Net revenues

$

31,803,387 

 

$

15,864,483 



The following table presents net revenue by geographic area for the years ended September 30, 2019 and 2018:





 

 

 

 

 



2019

 

2018



 

 

 

 

 

United States

$

17,260,174 

 

$

5,221,052 

Zimbabwe

 

*

 

 

2,159,263 

South Africa

 

*

 

 

2,960,677 

Other

 

14,543,213 

 

 

5,523,491 

Net revenues

$

31,803,387 

 

$

15,864,483 

* Less than 10% of total net revenues



The Company’s performance obligations consist mainly of transferring control of products identified in the contracts which occurs either when: i) the product is made available to the customer for shipment; ii) the product is shipped via common carrier; or iii) the product is delivered to the customer or distributor, in accordance with the terms of the agreement. Some of the Company’s contracts require the customer to make advanced payments prior to transferring control of the products. These advanced payments create a contract liability for the Company. The balances of the Company’s contract liability, included in accrued expenses and other current liabilities on the accompanying consolidated balances sheets, was approximately $249,000 and $4,000 at September 30, 2019 and 2018, respectively.



The Company records an unearned revenue liability if a customer pays consideration for product that was shipped by the Company but revenue recognition criteria have not been met under the terms of a contract; for example, if a distributor has a right to return product sold under certain conditions. Unearned revenue is recognized as revenue after control of the product is transferred to the customer and all revenue recognition criteria have been met. The Company had no unearned revenue at September 30, 2019. Unearned revenue at September 30, 2018 was approximately $187,000 and was comprised of sales made to a large distributor who had the right to return product under certain conditions.